[go: up one dir, main page]

MX2013011415A - Formulaciones que comprenden 2-amino-2-[2- (4-octil-fenil) -etil] -propano-1, 3-diol. - Google Patents

Formulaciones que comprenden 2-amino-2-[2- (4-octil-fenil) -etil] -propano-1, 3-diol.

Info

Publication number
MX2013011415A
MX2013011415A MX2013011415A MX2013011415A MX2013011415A MX 2013011415 A MX2013011415 A MX 2013011415A MX 2013011415 A MX2013011415 A MX 2013011415A MX 2013011415 A MX2013011415 A MX 2013011415A MX 2013011415 A MX2013011415 A MX 2013011415A
Authority
MX
Mexico
Prior art keywords
octylphenyl
diol
propane
formulations
ethyl
Prior art date
Application number
MX2013011415A
Other languages
English (en)
Other versions
MX342522B (es
Inventor
Supriya Rane
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45953284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013011415(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2013011415A publication Critical patent/MX2013011415A/es
Publication of MX342522B publication Critical patent/MX342522B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

Una composición farmacéutica sólida adecuada para su administración oral, la cual comprende: (a) un modulador del receptor SIP; (b) un relleno, y (c) una ciclodextrina.
MX2013011415A 2011-04-01 2012-03-30 Formulaciones que comprenden 2-amino-2-[2- (4-octil-fenil) -etil] -propano-1, 3-diol. MX342522B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161470747P 2011-04-01 2011-04-01
US201161545835P 2011-10-11 2011-10-11
PCT/US2012/031340 WO2012135561A1 (en) 2011-04-01 2012-03-30 Formulations comprising 2 -amino- 2- [2- (4 - octylphenyl) ethyl] propane -1, 3 - diol

Publications (2)

Publication Number Publication Date
MX2013011415A true MX2013011415A (es) 2013-12-09
MX342522B MX342522B (es) 2016-10-03

Family

ID=45953284

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011415A MX342522B (es) 2011-04-01 2012-03-30 Formulaciones que comprenden 2-amino-2-[2- (4-octil-fenil) -etil] -propano-1, 3-diol.

Country Status (35)

Country Link
US (5) US9592208B2 (es)
EP (2) EP3143990B1 (es)
JP (1) JP6019101B2 (es)
KR (1) KR102027014B1 (es)
CN (1) CN103476400B (es)
AR (1) AR085749A1 (es)
AU (1) AU2012236357B2 (es)
BR (1) BR112013024430B1 (es)
CA (1) CA2831600C (es)
CL (1) CL2013002810A1 (es)
CO (1) CO6771459A2 (es)
CY (2) CY1118423T1 (es)
DK (2) DK2694037T3 (es)
EA (2) EA027721B1 (es)
EC (1) ECSP13012912A (es)
ES (2) ES2610966T3 (es)
GT (1) GT201300227A (es)
HR (2) HRP20170021T1 (es)
HU (1) HUE031286T2 (es)
IL (1) IL228250B (es)
JO (1) JO3177B1 (es)
LT (2) LT3143990T (es)
MA (1) MA34981B1 (es)
MX (1) MX342522B (es)
MY (2) MY175633A (es)
PE (2) PE20170913A1 (es)
PH (1) PH12013501953A1 (es)
PL (2) PL3143990T3 (es)
PT (2) PT2694037T (es)
RS (1) RS59917B1 (es)
SG (1) SG193256A1 (es)
SI (2) SI3143990T1 (es)
TW (1) TWI528958B (es)
WO (1) WO2012135561A1 (es)
ZA (1) ZA201306636B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
CN103222966A (zh) * 2013-04-01 2013-07-31 北京万全德众医药生物技术有限公司 一种含有盐酸芬戈莫德的固体药物组合物及其制备方法
CA2920758A1 (en) * 2013-07-29 2015-02-05 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
US20170231928A1 (en) * 2014-08-22 2017-08-17 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
EP3247341A4 (en) * 2015-01-20 2018-12-19 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
EP3419607B1 (en) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Stable formulations of fingolimod
WO2021158838A1 (en) 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor modulator
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist
WO2025081920A1 (zh) * 2024-05-13 2025-04-24 苏州华健瑞达医药技术有限公司 一种芬戈莫德口服液体组合物及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5604229A (en) 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
SI0812588T1 (en) 1995-12-28 2005-02-28 Mitsubishi Pharma Corporation Pharmaceutical external preparations for topical administration comprising 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol for the treatment of diseases induced from immune disorder
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
PT990440E (pt) 1997-02-27 2009-02-05 Novartis Ag Composição farmacêutica compreendendo 2-amino-2-[2-(4-octilfenil)etil]propano-1,3-diol, uma lecitina e um sacárido
ES2226110T3 (es) 1997-04-04 2005-03-16 Mitsubishi Pharma Corporation Compuestos de 2-aminopropano-1,3-diol, su uso medico, e intermedios para sintetizarlos.
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP4627356B2 (ja) 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
AR043987A1 (es) * 2003-04-08 2005-08-17 Novartis Ag Composiciones farmaceuticas para administracion oral de agonistas del receptor de fosfato de esfingosina-1
WO2005025553A2 (en) * 2003-09-12 2005-03-24 Neuronova Ab Treatment of disorders of nervous systemsystem with fty720
US7888527B2 (en) 2004-12-06 2011-02-15 University Of Virginia Patent Foundation Aryl amide sphingosine 1-phosphate analogs
GB0502358D0 (en) * 2005-02-04 2005-03-16 Novartis Ag Organic compounds
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
BRPI0717570B8 (pt) * 2006-09-26 2021-05-25 Novartis Ag composição farmacêutica sólida adequada para administração oral, seu uso e seu processo de produção
MX2009006751A (es) 2006-12-21 2009-06-30 Abbott Lab Compuestos agonistas y antagonistas del receptor de esfingosina-1-fosfato.
MY159358A (en) * 2007-10-12 2016-12-30 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
KR20110086142A (ko) 2008-11-11 2011-07-27 노파르티스 아게 핑골리모드의 염
DK4098256T5 (da) 2008-12-22 2025-07-21 Novartis Ag Doseringsregime for en s1p-receptoragonist

Also Published As

Publication number Publication date
PE20170913A1 (es) 2017-07-12
EP2694037B1 (en) 2016-10-12
EP3143990B1 (en) 2019-11-27
EP3143990A1 (en) 2017-03-22
TWI528958B (zh) 2016-04-11
CN103476400A (zh) 2013-12-25
CY1122868T1 (el) 2021-05-05
HRP20170021T1 (hr) 2017-03-10
US9592208B2 (en) 2017-03-14
ES2773482T3 (es) 2020-07-13
GT201300227A (es) 2015-05-05
KR20140014194A (ko) 2014-02-05
PH12013501953A1 (en) 2023-11-25
PT3143990T (pt) 2020-03-04
ECSP13012912A (es) 2013-11-29
AU2012236357B2 (en) 2016-03-10
RS59917B1 (sr) 2020-03-31
SG193256A1 (en) 2013-10-30
EP2694037A1 (en) 2014-02-12
US20190247335A1 (en) 2019-08-15
ZA201306636B (en) 2014-05-28
WO2012135561A1 (en) 2012-10-04
US20200276137A1 (en) 2020-09-03
CY1118423T1 (el) 2017-06-28
DK3143990T3 (da) 2020-03-02
PL2694037T3 (pl) 2017-05-31
PH12013501953B1 (en) 2022-02-11
EA201391442A1 (ru) 2014-04-30
SI2694037T1 (sl) 2017-01-31
CL2013002810A1 (es) 2014-02-14
LT3143990T (lt) 2020-02-25
JP6019101B2 (ja) 2016-11-02
PL3143990T3 (pl) 2020-05-18
LT2694037T (lt) 2017-01-10
PE20140162A1 (es) 2014-02-12
IL228250B (en) 2020-09-30
US20170135967A1 (en) 2017-05-18
MY163746A (en) 2017-10-31
HK1190309A1 (zh) 2014-07-04
NZ615023A (en) 2016-07-29
JP2014509652A (ja) 2014-04-21
CN103476400B (zh) 2016-11-09
SI3143990T1 (sl) 2020-03-31
AU2012236357A1 (en) 2013-10-10
EA027721B1 (ru) 2017-08-31
US20180193291A1 (en) 2018-07-12
MY175633A (en) 2020-07-02
EA201790436A2 (ru) 2017-10-31
HUE031286T2 (hu) 2017-06-28
EA201790436A3 (ru) 2018-03-30
CA2831600A1 (en) 2012-10-04
BR112013024430A2 (pt) 2016-12-20
MX342522B (es) 2016-10-03
MA34981B1 (fr) 2014-03-01
BR112013024430B1 (pt) 2022-02-08
US20140371323A1 (en) 2014-12-18
DK2694037T3 (en) 2017-01-16
CA2831600C (en) 2020-04-21
AR085749A1 (es) 2013-10-23
JO3177B1 (ar) 2018-03-08
ES2610966T3 (es) 2017-05-04
PT2694037T (pt) 2017-01-17
KR102027014B1 (ko) 2019-09-30
TW201244711A (en) 2012-11-16
CO6771459A2 (es) 2013-10-15
HRP20200249T1 (hr) 2020-05-15
EA035686B1 (ru) 2020-07-27

Similar Documents

Publication Publication Date Title
JO3177B1 (ar) تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
CY1123434T1 (el) Λυοφιλοποiημενα νανοεναιωρηματα φαρμακων
PH12017501495A1 (en) Dosage regimen of an s1p receptor modulator
IL228709A0 (en) Dosage unit form for oral administration
PH12013502325A1 (en) Drug delivery system
UY34080A (es) Composición farmacéutica para administración oral que comprende fexofenadina y métodos de preparación
TN2013000396A1 (en) Formulations comprising 2 -amino- 2- [2- (4 - octylphenyl) ethyl] propane -1, 3 - diol
PL2714042T3 (pl) Przeciwbólowa kompozycja farmaceutyczna do podawania doustnego
AR124661A2 (es) Formulaciones
EA201992463A1 (ru) Система доставки лекарственного средства
CR8977A (es) Dosis altas de formulaciones de ibandronato

Legal Events

Date Code Title Description
FG Grant or registration